IRBESARTAN I NEFROPROTEKTsIYa: VLIYaNIE NA TUBULOINTERSTITsIAL'NUYu TKAN' I FUNKTsIYu POChKI V TsELOM


Cite item

Full Text

Abstract

В многочисленных исследованиях показаны плейотропные эффекты и нефропротективное действие блокаторов кальциевых каналов (БРА), в частности ирбесартана, у больных артериальной гипертензией (АГ) и сахарным диабетом 2 типа. В статье представлены литературные данные, на основании которых препараты класса БРА могут рассматриваться в качестве терапии первой линии у пациентов с АГ, особенно относящихся к категории высокого риска осложнений. Данный класс антигипертензивных лекарственных средств перспективен в связи с рядом потенциальных, еще недостаточно изученных свойств - антифибротических, противовоспалительных, а также возможности сохранения почечной функции у пациентов на гемодиализе.

References

  1. Johnson Rj, Herrera-Acosta J, Schreiner G, et al. Subtle acquired renal injury as a mechanism of salt-sensitive hypertension. N Engl J Med 2002;346:913-23.
  2. Eknoyan G, McDonald MA, Appel D, et al. Chronic tubulointerstitial nephritis: correlation between structural and functional findings. Kidney Int 1990;38:736-43.
  3. Eknoyan G. Chronic tubulointerstitial nephropathies. In Diseases of the Kidney, edn 6. Edited by Schrier RW, Gottschalk CW. Boston: Little Brown, 1997:1983-2015.
  4. Kriz W, Lehir M. Pathways to nephron loss starting from glomerular diseases-Insights from animal models. Kidney Int 2005;67:404-19.
  5. Tylicki L, Manitius J, Lysiak-Szydlowskaw, et al. Tubular injury: The first symptom of hypertensive kidney involvement? Med Sci Monit 9:CR135-CR41, 2003
  6. Rodr´Iguez-Iturbe B, Richard JJ, Herrera-Acosta J. Tubulointerstitial damage and progression of renal failure, Kidney Int 2005;68(99):82-6.
  7. Schmieder RE, Ruilope LM, Barnett AH. Renal protection with angiotensin receptor blockers: where do we stand. J Nephrol 2011 Mar 9. pii: D81BC873-D6D3-4D2C-AEE9-CD0EDDA3BD35.
  8. Bakris G. Are there effects of renin-angiotensin system antagonists beyond blood pressure control? Am J Cardiol. 2010;105(1):21A-9A.
  9. Fujino M, Miura S, Kiya Y, et al. A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects. Hypert Res 2010;33:1044-52; doi: 10.1038/hr.2010.135.
  10. Whaley-Connell A, Nistala R, Habibi J, et al. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2010;298(3):655-61.
  11. Matsui T, Yamagishi S, Takeuchi M, et al. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res 2010;61(1):34-9.
  12. von zur Muhlen B, Kahan T, Hagg A, et al. Treatment with irbesartan or atenolol improves endothelial function in essential hypertension. J Hypertens 2001;19(10):1813-8.
  13. ESH-ESC Guidelines Committee. 2007 guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-87.
  14. Ravera M, Ratto E, Vettoretti S, et al. Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation J Am Soc Nephrol 2005;16:48-52. doi: 10.1681/ASN.2004110957
  15. Matsui T, Yamagishi S, Ueda S, et al. Irbesartan inhibits albumin-elicited proximal tubular cell apoptosis and injury in vitro. Protein Pept Lett 2010;17(1):74-7.
  16. Ren X, Guan G, Liu G, et al. Irbesartan ameliorates diabetic nephropathy by reducing the expression of connective tissue growth factor and alpha-smooth-muscle actin in the tubulointerstitium of diabetic rats. Pharmacology 2009;83(2):80-7.
  17. Zhao G, Zhao H, Tu L, et al. Effects and mechanism of irbesartan on tubulointerstitial fibrosis in 5/6 nephrectomized rats. J Huazhong Univ Sci Technolog Med Sci 2010;30(1):48-54.
  18. Rossing K, Schjoedt KJ, Jensen BR, et al. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria Kidney Int 2005;68:1190-98.
  19. www.clinicaltrials.gov Bramlage P, Durand-Zaleski I, Desai N, et al. The value of irbesartan in the management of hypertension. Expert Opin Pharmacother 2009;10(11):1817-31.
  20. Bramlage P, Schindler C. Differences in pharmacology and their translation into differences in clinical efficacy--a comparison of the renin angiotensin blocking agents irbesartan and losartan. Expert Opin Pharmacother 2010;11(4):521-35.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies